Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.62 |
| ▸ | PPARA | Q07869 | 6/20 | 0.61 |
| ▸ | PPARG | P37231 | 4/20 | 0.61 |
| ▸ | PPARD | Q03181 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5217215 | 1.00 | ACE (0.62) | ACEPPARAPPARGPPARD | |
| SCHEMBL8997911 | 1.00 | ACE (0.62) | ACEPPARAPPARGPPARD | |
| SCHEMBL14383383 | 0.84 | ACE (0.59) | ACEPPARAPPARGPPARD | |
| SCHEMBL14405000 | 0.84 | ACE (0.59) | ACEPPARAPPARGPPARD | |
| SCHEMBL7283024 | 0.84 | ACE (0.67) | ACEPPARAPPARGPPARD | |
| SCHEMBL7282451 | 0.84 | ACE (0.67) | ACEPPARAPPARGPPARD | |
| SCHEMBL2778639 | 0.84 | ACE (0.67) | ACEPPARAPPARGPPARD | |
| SCHEMBL5610149 | 0.83 | ACE (0.58) | ACEPPARAPPARGPPARD | |
| SCHEMBL3963130 | 0.83 | ACE (0.58) | ACEPPARAPPARGPPARD | |
| SCHEMBL3963125 | 0.83 | ACE (0.58) | ACEPPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192173-A1 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | SEQUELLA, INC. | 2009-07-30 | — | — | US | disclosed |
| US-5587506-A | ADDING A BENZYLOXYCARBONYL BLOCKED AMINO ACID TO A SOLUTION OF SODIUM TERT-BUTOXIDE IN A NON-PROTIC SOLVENT FOLLOWED BY ADDITION OF DIMETHYL SULFATE | BASF AKTIENGESELLSCHAFT (DE) | 1996-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192173-A1 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | RIF1, TERT, ELL | ACE 54/4885PPARA 575/4885PPARG 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.